Semaglutide and Eye Side Effects: What the Evidence Actually Shows

Why rapid weight loss can change what you see

One of the less obvious mechanisms behind eye symptoms on semaglutide is speed. When blood-glucose levels fall quickly (which can happen in the early weeks of treatment, especially in people with diabetes) the lens of the eye changes shape slightly in response to shifting fluid balance. This can produce temporary blurred vision that has nothing to do with structural eye damage. Most people who notice this find it resolves within a few weeks as their body adjusts.

This does not mean you should ignore it. Blurred vision that appears after starting semaglutide, or that worsens rather than settles, needs a conversation with a clinician. The NHS semaglutide medicines page lists vision changes among the side effects to watch for, alongside the more familiar gastrointestinal ones. If you are mid-treatment and unsure whether what you are experiencing is normal adjustment or something that needs attention, the prescribers at our support team are available seven days a week.

The practical takeaway: blurred vision in the first few weeks, mild and improving, is a known early effect. For a closer look at how these visual changes present specifically with Wegovy, our guide to how Wegovy can affect the eyes covers what to expect at each stage of treatment. Blurred vision that starts suddenly, is severe, or involves other visual disturbances such as floaters or loss of peripheral sight is a different matter entirely, see the section below on when to get medical help.

The diabetic retinopathy signal: what the trial data found

The more clinically significant concern emerged in the SUSTAIN-6 cardiovascular trial of semaglutide, which found a higher rate of diabetic retinopathy complications in the semaglutide group compared with placebo. This was not a weight-management trial (participants had type 2 diabetes and established cardiovascular disease) but the finding was notable enough to be included in semaglutide's prescribing information and is discussed in detail on the eMC SmPC for semaglutide.

The proposed explanation relates, again, to speed. People with long-standing poorly controlled diabetes who experience a rapid drop in HbA1c may see a temporary worsening of retinopathy, a phenomenon also documented with insulin and other glucose-lowering therapies, not unique to semaglutide. The absolute risk in the SUSTAIN-6 data was small, and later, larger trials have not consistently replicated the signal in the same way, but the caution remains in the licence.

For people taking Wegovy for weight management without diabetes, the clinical picture is different. The retinopathy signal is most relevant where there is pre-existing diabetic eye disease. That said, if you have any degree of diabetic retinopathy, your prescriber needs to know, it is a standard part of the medical history review, not an automatic exclusion, but a factor that shapes how your care is managed. You can read more about the full range of semaglutide side effects in the context of weight management treatment.

The decision you are actually making: is the benefit worth the risk for your eyes?

This is where the SK3 frame matters most. If you have healthy eyes, no diabetes and no significant risk factors for retinal disease, the eye-specific risk profile of semaglutide for weight management is modest. The clinical trials that inform NICE's appraisal of semaglutide (summarised at NICE TA875) did not identify eye complications as a primary safety concern for the weight-management population.

If you have diabetes alongside obesity, the picture is more nuanced. The potential cardiovascular and metabolic benefits of semaglutide are substantial, and NICE's guidance weighs those benefits in context. But a baseline eye examination is sensible before starting treatment, and our page on how semaglutide affects the eyes explains what your prescriber will be looking for in your history and why it matters for monitoring.

If you wear contact lenses and notice your prescription feels off in the early weeks (a subtler version of the lens-shape change described above) this is worth mentioning at your next routine eye appointment rather than treating as an emergency. Keep your treatment in your usual cool storage spot (some people find the fridge door the most consistent place) so one variable stays constant while your body is adjusting to another.

For a broader view of how semaglutide's side effects are managed in practice, the Wegovy side effects guide covers the full spectrum, including how the dose-escalation schedule is designed to reduce symptom burden from the start.

When to get medical help, and how to report what you notice

Some eye symptoms during semaglutide treatment need prompt medical attention. Stop and seek urgent help (call 111 or attend urgent care) if you experience any of the following: sudden loss of vision in one or both eyes; a new curtain or shadow across your visual field; a sudden increase in floaters, especially with flashing lights; or eye pain combined with redness and visual disturbance. These are not typical semaglutide adjustment symptoms. They are signals that something else may be happening, whether or not it is directly caused by the medicine.

For less urgent but persistent symptoms (blurred vision that has not improved after four to six weeks, noticeable changes to colour perception, or any eye change that simply does not feel right) contact your prescriber before your next scheduled review. Do not wait until a repeat consultation to mention it.

The MHRA's Yellow Card scheme exists precisely for situations like this. Even if you are unsure whether your eye symptom is related to semaglutide, reporting it at yellowcard.mhra.gov.uk contributes to the post-market safety monitoring that keeps prescribing guidance current. You can also flag it directly through our aftercare team, who are available seven days a week and will escalate clinical concerns to a prescriber the same day.

If you are still at the stage of deciding whether to start treatment and want to discuss your eye history as part of that decision, our prescribers cover this as a standard part of the free consultation at the nume consultation page. A clinical assessment (not a checkbox form) is how suitability is established.